Despite a challenging year for research funding, PNRI scientists moved discovery forward with 21 studies in the past year, shedding light on genetic disorders, cancer biology, and hidden patterns in the human genome – breakthroughs that demonstrate the impact of continued investment in biomedical research.
PNRI lists its 45,000-sq-ft headquarters at 720 Broadway in Seattle for sale to position the institute for future research sustainability and growth.
From cancer in clams to rare disease genomics, PNRI’s 2025 SURI interns spent the summer tackling big questions through hands-on research.
New research from PNRI’s Carvalho Lab reveals how complex genomic rearrangements like inversions may help solve rare disease cases that defy standard diagnosis.
PNRI welcomes new COO Mark Rieder, PhD, and honors retiring CEO Jack Faris, PhD, marking a new chapter in advancing genetic research.
Listen now to PNRI Science: Rare Disease, Real Progress – our latest podcast series featuring conversations from our 2025 Rare Disease Day Symposium with scientists, advocates, and industry leaders accelerating rare disease research.
PNRI’s FY24 Annual Report is here! See how we’re advancing genetic research, expanding programs, and shaping the future of human health.
PNRI’s inaugural Rare Disease Day symposium ignited bold collaborations to accelerate rare disease research. See how scientists, clinicians, and advocates are driving breakthroughs!
Federal funding cuts disrupt research critical to medical advancements, impacting those needing diagnoses, treatments, and cures. Read PNRI’s op-ed in The Seattle Times to learn more.
Federal funding disruptions have stalled research, delaying critical discoveries. PNRI’s leaders share why stable support matters and how we can protect scientific progress. Read our special message.